NCT01464138 | Jomaa Pharma GmbH|Fundacio Clinic Barcelona|Hospital Clinic of Barcelona | Malaria | September 2010 | Phase 2 |
NCT00352612 | Aaron Chen|Thrasher Research Fund|Johns Hopkins University | Staphylococcal Infection|Abscess|Staphylococcal Skin Infection|Folliculitis | September 2006 | Phase 4 |
NCT02595034 | Taro Pharmaceuticals USA | Acne Vulgaris | January 2015 | Phase 1 |
NCT03261830 | Sumit Gupta|University of Missouri-Columbia | Supracondylar Humerus Fracture|Post Operative Wound Infection | August 18, 2017 | Phase 4 |
NCT05137119 | University of Melbourne|Berry Consultants|McGill University Health Centre+Research Institute of the McGill University Health Centre|Menzies School of Health Research|Middlemore Clinical Trials|Queensland University of Technology|Sunnybrook Health Sciences Centre|Tan Tock Seng Hospital|Telethon Kids Institute|The Peter Doherty Institute for Infection and Immunity|The University of Queensland | Staphylococcus Aureus Bacteremia | February 16, 2022 | Phase 4 |
NCT05762484 | Erasmus Medical Center | Hidradenitis Suppurativa, Acne Inversa | April 2023 | Not Applicable |
NCT00664248 | Dow Pharmaceutical Sciences | Acne Vulgaris | October 2006 | Phase 3 |
NCT04516148 | Medstar Health Research Institute | Burn|Surgery|Infection Wound | May 29, 2018 | Phase 4 |
NCT02579161 | Northwell Health | Kidney Stones | September 2014 | Phase 3 |
NCT01769235 | Taro Pharmaceuticals USA | Acne Vulgaris | November 2012 | Phase 1 |
NCT05398679 | Fundacion Clinic per a la Recerca Biomédica | Endocarditis Infective | June 1, 2022 | Phase 4 |
NCT00713609 | Stiefel, a GSK Company|GlaxoSmithKline | Acne Vulgaris | June 2008 | Phase 2 |
NCT00776919 | Stiefel, a GSK Company|Rho, Inc.|Quintiles, Inc.|GlaxoSmithKline | Acne Vulgaris | October 2008 | Phase 3 |
NCT03779360 | Centre for Human Drug Research, Netherlands|Maruho Co., Ltd. | Inflammation; Skin | October 12, 2018 | Not Applicable |
NCT01619410 | University of Chicago|Pfizer | Skin Diseases, Bacterial|Abscess | January 2012 | Not Applicable |
NCT01500837 | Assistance Publique - Hôpitaux de Paris | Osteoarticular Infection | October 2010 | Not Applicable |
NCT02141217 | GlaxoSmithKline | Focal Infection, Dental | March 21, 2013 | Phase 4 |
NCT01744730 | Phillip Brian Smith|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|The Emmes Company, LLC|Duke University | Bacterial Infections|Obesity | June 2013 | Phase 1 |
NCT00663286 | Dow Pharmaceutical Sciences | Acne Vulgaris | October 2006 | Phase 3 |
NCT01769664 | Taro Pharmaceuticals USA | Acne Vulgaris | September 2012 | Phase 1 |
NCT05899140 | Frieder Schaumburg|Westfälische Wilhelms-Universität Münster | Skin Infection|Staphylococcal Infections|Staphylococcus Aureus Infection | August 1, 2023 | Phase 4 |
NCT04067531 | Skaraborg Hospital | Infection, Bacterial | August 1, 2020 | Phase 3 |
NCT02578043 | Taro Pharmaceuticals USA | Acne Vulgaris | April 2015 | Phase 1 |
NCT00642980 | University Hospital, Lille|Pfizer | Pregnancy | April 2006 | Phase 4 |
NCT01915732 | GlaxoSmithKline | Acne Vulgaris | April 2013 | Phase 3 |
NCT03522441 | Akorn, Inc. | Acne Vulgaris | April 27, 2018 | Phase 3 |
NCT01127880 | St. Luke´s Hospital, Pennsylvania | Hemopneumothorax|Pneumothorax | July 2005 | Phase 2|Phase 3 |
NCT00616330 | Lumara Health, Inc. | Vulvovaginitis|Vaginitis | January 2008 | Phase 3 |
NCT00729937 | National Institute of Allergy and Infectious Diseases (NIAID) | Staphylococcal Infection | April 2009 | Phase 2|Phase 3 |
NCT01111994 | Callender Center for Clinical Research|Society Hill Dermatology | Acne | November 2009 | Phase 4 |
NCT00377000 | Sanofi | Acne Vulgaris | November 2005 | Phase 4 |
NCT01293643 | Merck Sharp & Dohme LLC | Vaginosis, Bacterial|Candidiasis, Vulvovaginal | May 2010 | Phase 3 |
NCT03883269 | Centre for Human Drug Research, Netherlands|Maruho Co., Ltd. | Acne Vulgaris | March 20, 2018 | Phase 4 |
NCT01800825 | Christiana Care Health Services|Jawaharlal Nehru Medical College|Thrasher Research Fund | Pregnancy|Prematurity|Preterm Birth|Bacterial Vaginosis | July 2013 | Phase 4 |
NCT02809131 | Vanderbilt University Medical Center|Thomas Jefferson University|The Cooper Health System|Valley Health System|Medtronic | Sick Sinus Syndrome|Complete Heart Block|Syncope|Chronic Systolic Heart Failure | April 1, 2016 | Phase 3 |
NCT01722708 | HaEmek Medical Center, Israel | Abnormal Vaginal Flora|Clindamycin Vs Metronidazole|High Risk Pregnancies for Preterm Labor | April 2012 | Not Applicable |
NCT00361322 | Hadassah Medical Organization | Acne Vulgaris | April 2005 | Phase 1|Phase 2 |
NCT03945357 | Prisma Health-Upstate|Washington University School of Medicine|The Cleveland Clinic|Penn State University|Oregon Health and Science University|Ohio State University|New Hanover Regional Medical Center|University of Pennsylvania | Ventral Hernia Repair | May 15, 2019 | Phase 3 |
NCT00823901 | Massachusetts General Hospital|Medicis Pharmaceutical Corporation | Rosacea | February 2009 | Phase 2|Phase 3 |
NCT05177198 | Cairo University | Periodontal Intrabony Defects | March 2022 | Not Applicable |
NCT03033472 | Cairo University | Symptomatic Periapical Periodontitis | | Phase 2|Phase 3 |
NCT01823523 | Atlantic Center for Oral and Maxillofacial Surgery | Dentofacial Deformity | June 2013 | Not Applicable |
NCT00836004 | Teva Pharmaceuticals USA | Healthy | November 2003 | Phase 1 |
NCT03080740 | Guangzhou Yipinhong Pharmaceutical CO.,LTD | Bacterial Vaginosis | July 2016 | Phase 4 |
NCT00814905 | United States Naval Medical Center, Portsmouth | Chorioamnionitis | June 2009 | Not Applicable |
NCT03717506 | Gage Development Company, LLC | Acne Vulgaris | October 10, 2018 | Phase 3 |
NCT01052246 | Laserklinik Karlsruhe | Acne Vulgaris | October 2008 | Not Applicable |
NCT01796665 | Padagis LLC | Acne | February 2012 | Phase 3 |
NCT00000717 | National Institute of Allergy and Infectious Diseases (NIAID) | Pneumonia, Pneumocystis Carinii|HIV Infections | | Not Applicable |
NCT00219570 | Pfizer|Parexel|SACT INTERNATIONAL Co., LTD.|Acronet|Bellsystem24 , Inc.|Mitsubishi Kagaku Bio-Clinical Laboratories, inc|SATO Pharmaceutical Co., Ltd. | Acne Vulgaris | January 2005 | Phase 4 |
NCT01063270 | Henry Ford Health System | Hidradenitis Suppurativa | February 2010 | Not Applicable |
NCT03779295 | West Virginia University | Perioral Dermatitis | November 1, 2018 | Not Applicable |
NCT04321070 | Taro Pharmaceuticals USA | Acne Vulgaris | September 9, 2019 | Phase 1 |
NCT00694928 | Lumara Health, Inc. | Vaginal Infection | May 2008 | Phase 3 |
NCT00887484 | Stiefel, a GSK Company|GlaxoSmithKline | Acne Vulgaris | February 2009 | Phase 4 |
NCT04134273 | Taro Pharmaceuticals USA | Acne Vulgaris | March 20, 2019 | Phase 1 |
NCT00473083 | British Columbia Cancer Agency|Hoffmann-La Roche | Rash | January 2009 | Phase 2 |
NCT00398658 | Shahid Beheshti University of Medical Sciences | Endophthalmitis|Prophylaxy of Post Traumatic Endophthalmitis|Bacterial Endophthalmitis | March 2002 | Phase 4 |
NCT02314806 | Hospital General Universitario Elche | Breast Cancer | January 2013 | Phase 3 |
NCT04469075 | Memorial Sloan Kettering Cancer Center | Glioblastoma|Recurrent Glioblastoma|Skin Toxicity | July 9, 2020 | Phase 2 |
NCT01047189 | Wake Forest University|Medicis Pharmaceutical Corporation|Wake Forest University Health Sciences | Acne Vulgaris | March 2009 | Phase 4 |
NCT02721173 | All India Institute of Medical Sciences, Bhubaneswar | Acne Vulgaris | April 2016 | Phase 4 |
NCT04502095 | Roswell Park Cancer Institute | Bladder Carcinoma|Refractory Bladder Carcinoma|Urinary Tract Infection | September 2, 2020 | Phase 4 |
NCT04104178 | Hvidovre University Hospital | MRSA|MRSA Colonization | May 20, 2020 | Phase 3 |
NCT03560232 | Mercy Health Ohio | Open Fracture|Post-Op Wound Infection | July 9, 2018 | Phase 4 |
NCT01945450 | Hadassah Medical Organization | Endometritis | January 2014 | Not Applicable |
NCT01361269 | Zentopharm GmbH|Albert Schweitzer Hospital|Centro de Investigacao em Saude de Manhica | Malaria | June 2011 | Phase 2 |
NCT00964366 | Stiefel, a GSK Company|GlaxoSmithKline | Acne Vulgaris | July 2009 | Phase 4 |
NCT00911573 | Wyeth is now a wholly owned subsidiary of Pfizer | Skin Diseases|Infection | August 2011 | Phase 3 |
NCT04980170 | Jordan University Hospital | Antibiotics Causing Adverse Effects in Therapeutic Use | November 1, 2021 | Early Phase 1 |
NCT01374581 | Universiteit Antwerpen|European and Developing Countries Clinical Trials Partnership (EDCTP)|Fund for Scientific Research, Flanders, Belgium|Institute of Tropical Medicine, Belgium|University of Kinshasa|Centre Muraz|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Makerere University | Malaria | May 2012 | Phase 3 |
NCT01015638 | Stiefel, a GSK Company|GlaxoSmithKline | Acne Vulgaris | August 2009 | Phase 4 |
NCT00926367 | Stiefel, a GSK Company|GlaxoSmithKline | Acne Vulgaris | May 2009 | Phase 4 |
NCT01132443 | Stiefel, a GSK Company|GlaxoSmithKline | Acne Vulgaris | May 6, 2010 | Phase 1 |
NCT00000640 | National Institute of Allergy and Infectious Diseases (NIAID)|Jacobus Pharmaceutical|Glaxo Wellcome | Pneumonia, Pneumocystis Carinii|HIV Infections | | Phase 3 |
NCT01715610 | Lawson Health Research Institute | Peritonsillar Abscess | May 24, 2012 | Not Applicable |
NCT01792804 | Heinrich-Heine University, Duesseldorf|German Research Foundation | Staphylococcus Aureus Infection | December 2013 | Phase 3 |
NCT03478163 | Cedars-Sinai Medical Center | Obstetric Complication|Postpartum Hemorrhage|Postpartum Endometritis | March 8, 2018 | Phase 4 |
NCT01422785 | Zeichner, Joshua, M.D. | Acne Vulgaris | July 2011 | Phase 4 |
NCT02465632 | Glenmark Pharmaceuticals Ltd. India | Acne Vulgaris | April 2015 | Phase 3 |
NCT02058628 | GlaxoSmithKline | Acne Vulgaris | February 21, 2014 | Phase 4 |
NCT02782078 | Assistance Publique - Hôpitaux de Paris | Staphylococcal Infections | March 6, 2017 | Not Applicable |
NCT00836056 | Teva Pharmaceuticals USA | Healthy | November 2003 | Phase 1 |
NCT02005666 | Zydus Lifesciences Limited | Acne Vulgaris | November 2013 | Phase 3 |
NCT01138514 | Padagis LLC | Acne Vulgaris | October 2009 | Phase 3 |
NCT01400867 | Forest Laboratories|AstraZeneca | Infections, Pediatrics | December 2011 | Phase 2|Phase 3 |
NCT01498744 | Ann & Robert H Lurie Children´s Hospital of Chicago | Abscess Soft Tissue|Methicillin-resistant Staphylococcus Aureus (MRSA) Infection|Skin Abscess | February 2010 | Not Applicable |
NCT02210689 | Actavis Inc.|Watson Laboratories, Inc. | BACTERIAL VAGINOSIS|Signs and Symptoms to be Evaluated and Recorded Include|Vaginal Discharge Color, Odor, and Consistency|Vulvovaginal Itching and Irritation (Subjective) Absent, Mild, Moderate, or Severe|Vulvovaginal Inflammation (Objective) Absent, Mild, Moderate, or Severe | January 2014 | Phase 3 |
NCT03476941 | Paolo Goffredo|University of Iowa | Abdominal Abscess | April 1, 2019 | Phase 2 |
NCT01788384 | Watson Laboratories, Inc. | Acne Vulgaris | July 2012 | Phase 3 |
NCT02585141 | University of Southern Denmark|Odense University Hospital | Anal Fistulas | October 2015 | Not Applicable |
NCT04194216 | Stanford University|Washington University School of Medicine|Vanderbilt University School of Medicine|University of Washington|Duke University|Harvard University|University of Kansas Medical Center|University of Cincinnati|Loma Linda University | Nasal Obstruction|Nasal Surgical Procedures | May 20, 2020 | Phase 3 |
NCT05846399 | University of Missouri-Columbia | Cat Bite|Hand Injuries|Arm Injury|Infection, Bacterial|Anti-bacterial Agents | September 1, 2023 | Phase 4 |
NCT02018094 | Hull University Teaching Hospitals NHS Trust|University of Hull | Wound Infection|Amputation Wound | October 8, 2013 | Phase 4 |
NCT03173053 | Radboud University Medical Center|ZonMw: The Netherlands Organisation for Health Research and Development|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|University College, London | Staphylococcus Aureus|Motility Disorder | February 8, 2018 | Not Applicable |
NCT01757236 | University Hospital, Tours|Pfizer|International Clinical Trials Association | Hip Prosthetic Joint Infection | October 2012 | Phase 2 |
NCT00000674 | National Institute of Allergy and Infectious Diseases (NIAID)|Upjohn|Glaxo Wellcome | Toxoplasmosis, Cerebral|HIV Infections | | Not Applicable |
NCT02475876 | Michael Cohen-Wolkowiez|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Duke University | Bacterial Infections | November 2015 | Phase 1 |
NCT01016977 | Stiefel, a GSK Company|GlaxoSmithKline | Acne Vulgaris | October 2009 | Phase 4 |
NCT01874860 | University of Louisville|James Graham Brown Cancer Center | Colorectal Cancer|Head and Neck Cancer | August 2013 | Phase 2 |
NCT05582434 | Wake Forest University Health Sciences|Bausch Health Americas, Inc. | Acne | August 2023 | Early Phase 1 |
NCT00730028 | National Institute of Allergy and Infectious Diseases (NIAID) | Staphylococcal Infection | April 2009 | Phase 2 |
NCT04349410 | The Camelot Foundation | CoVid 19 Positive | April 11, 2020 | Phase 2|Phase 3 |
NCT05867654 | University of Louisville|Osteo Science Foundation | Osteomyelitis of Jaw | May 1, 2023 | |
NCT00837213 | Stiefel, a GSK Company|GlaxoSmithKline | Acne | August 2007 | Phase 4 |
NCT05223400 | Alexandria University | Infection, Bacterial | March 1, 2022 | |
NCT04723940 | Rothman Institute Orthopaedics | Joint Infection | January 25, 2021 | Phase 3 |
NCT03374176 | Centro Universitario de Tonalá | Periodontitis|Periodontal Pocket|Diabetes Mellitus | March 2014 | Phase 3 |
NCT01155154 | State University of New York - Downstate Medical Center|Staten Island University Hospital|Kings County Hospital Center | Simple Hand Lacerations | February 2010 | Not Applicable |
NCT02730962 | University of Minnesota | Pre-Diabetes | June 2016 | Phase 2 |
NCT05926869 | Jinnah Postgraduate Medical Centre | Acne Vulgaris | August 1, 2022 | Phase 2 |
NCT03615768 | Lee´s Pharmaceutical Limited|Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | Acne Vulgaris | August 14, 2018 | Phase 3 |
NCT03234517 | Zagazig University | Bacterial Vaginosis Treatment | August 1, 2016 | Phase 2 |
NCT03511118 | Duke University|The Emmes Company, LLC|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Lactating Women on Select DOI|Breastfed Infants of Mothers on Select DOI | October 4, 2018 | |
NCT00503542 | Agency for Healthcare Research and Quality (AHRQ) | Vaginitis | February 2007 | Early Phase 1 |
NCT02593383 | Lee´s Pharmaceutical Limited | Acne | March 1, 2015 | Phase 1|Phase 2 |
NCT00214643 | Albert Schweitzer Hospital | Malaria | June 2005 | Phase 3 |
NCT01876628 | University Hospitals Bristol and Weston NHS Foundation Trust|University of Bristol|Public Health England | Cellulitis | October 2013 | Phase 4 |
NCT02309346 | Hospital de Clinicas de Porto Alegre | Septic Abortion | December 31, 2014 | Phase 4 |
NCT00889356 | Zodiac Produtos Farmaceuticos S.A. | Candidiasis|Bacterial Vaginosis | September 2009 | Phase 3 |
NCT02860845 | Laboratorios Ordesa|Clever Instruments S.L. | Candidiasis|Vaginosis, Bacterial | July 12, 2016 | Phase 4 |
NCT03257202 | University of Southern California | Surgical Site Infection | September 11, 2017 | Phase 2 |
NCT01994993 | Michael Cohen-Wolkowiez|The Emmes Company, LLC|Duke University | Complicated Intra Abdominal Infections | December 2013 | Phase 2|Phase 3 |
NCT00964223 | Stiefel, a GSK Company|GlaxoSmithKline | Acne Vulgaris | July 2009 | Phase 4 |
NCT01125410 | Medinova AG | Bacterial Vaginosis | January 2007 | Phase 3 |
NCT00002064 | Palo Alto Medical Foundation|NIH AIDS Clinical Trials Information Service | Toxoplasmosis, Cerebral|HIV Infections | | Not Applicable |
NCT05166746 | Peter Humaidan|Regionshospitalet Viborg, Skive | Bacterial Vaginoses|Infertility, Female | December 7, 2017 | Phase 2 |